LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 6 of total 6

Search options

  1. Article ; Online: Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.

    Zanwar, Saurabh / Abeykoon, Jithma Prasad / Kapoor, Prashant

    Current hematologic malignancy reports

    2020  Volume 15, Issue 1, Page(s) 31–43

    Abstract: Purpose of review: Recent advances the genomic profiling of patients with Waldenström macroglobulinemia (WM) have led to the identification of novel therapeutic targets in these patients. In this review, we cover the current standard of care and the ... ...

    Abstract Purpose of review: Recent advances the genomic profiling of patients with Waldenström macroglobulinemia (WM) have led to the identification of novel therapeutic targets in these patients. In this review, we cover the current standard of care and the recently evaluated novel approaches with high potential to be incorporated in the therapeutic armamentarium against WM.
    Recent findings: The MYD88
    MeSH term(s) Agammaglobulinaemia Tyrosine Kinase/antagonists & inhibitors ; Agammaglobulinaemia Tyrosine Kinase/metabolism ; Animals ; Genetic Predisposition to Disease ; Humans ; Molecular Targeted Therapy/adverse effects ; Mutation ; Myeloid Differentiation Factor 88/genetics ; Myeloid Differentiation Factor 88/metabolism ; Phosphoinositide-3 Kinase Inhibitors/therapeutic use ; Proteasome Inhibitors/adverse effects ; Proteasome Inhibitors/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors ; Proto-Oncogene Proteins c-bcl-2/metabolism ; Receptors, CXCR4/antagonists & inhibitors ; Receptors, CXCR4/genetics ; Receptors, CXCR4/metabolism ; Signal Transduction/drug effects ; Waldenstrom Macroglobulinemia/drug therapy ; Waldenstrom Macroglobulinemia/enzymology ; Waldenstrom Macroglobulinemia/genetics
    Chemical Substances BCL2 protein, human ; CXCR4 protein, human ; MYD88 protein, human ; Myeloid Differentiation Factor 88 ; Phosphoinositide-3 Kinase Inhibitors ; Proteasome Inhibitors ; Protein Kinase Inhibitors ; Proto-Oncogene Proteins c-bcl-2 ; Receptors, CXCR4 ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2) ; BTK protein, human (EC 2.7.10.2)
    Language English
    Publishing date 2020-01-31
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2229765-0
    ISSN 1558-822X ; 1558-8211
    ISSN (online) 1558-822X
    ISSN 1558-8211
    DOI 10.1007/s11899-020-00559-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6332: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population.

    Zanwar, Saurabh / Abeykoon, Jithma Prasad / Kapoor, Prashant

    Current hematologic malignancy reports

    2019  Volume 14, Issue 2, Page(s) 70–82

    Abstract: Purpose of review: Approximately one half of the patient-population in multiple myeloma (MM) is > 70 years at diagnosis. Despite notable strides in the management and improved survival, MM remains incurable, with an increasing proportion of elderly ... ...

    Abstract Purpose of review: Approximately one half of the patient-population in multiple myeloma (MM) is > 70 years at diagnosis. Despite notable strides in the management and improved survival, MM remains incurable, with an increasing proportion of elderly patients comprising the relapsed-refractory cohort.
    Recent findings: The arbitrary age cutoff at 65 years to define the elderly patient-population has evolved to a more nuanced categorization, incorporating a comprehensive assessment for determining frailty prior to commencing treatment. This step is critical in determining the therapy-intensity, including transplant-eligibility, to minimize toxicity. Dose-modifications are crucial, as the merits of continuous therapy are becoming evident in this patient-population. Bortezomib, lenalidomide, and dexamethasone (VRd) combination has emerged as standard of care for newly diagnosed MM. Fixed-duration Rd followed by reduced-dosed continuous R may be considered in select frail patients with standard-risk MM. Herein, we review the unique challenges encountered in elderly MM and discuss strategies for optimal management.
    MeSH term(s) Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib/administration & dosage ; Dexamethasone/administration & dosage ; Geriatric Assessment/methods ; Geriatric Assessment/statistics & numerical data ; Humans ; Lenalidomide/administration & dosage ; Multiple Myeloma/drug therapy ; Multiple Myeloma/pathology ; Outcome Assessment, Health Care/methods ; Outcome Assessment, Health Care/statistics & numerical data ; Survival Analysis
    Chemical Substances Bortezomib (69G8BD63PP) ; Dexamethasone (7S5I7G3JQL) ; Lenalidomide (F0P408N6V4)
    Language English
    Publishing date 2019-02-28
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2229765-0
    ISSN 1558-822X ; 1558-8211
    ISSN (online) 1558-822X
    ISSN 1558-8211
    DOI 10.1007/s11899-019-00500-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6332: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: C3+ and C3- warm autoimmune hemolytic anemias: A comparison of clinical characteristics and treatment outcomes.

    Nunnelee, Jordan / Abeykoon, Jithma Prasad / Ashrani, Aneel A / Elliott, Michelle Ann / Hook, C Christopher / Pardanani, Animesh / Pruthi, Rajiv K / Rouse, Rachelle L / Sridharan, Meera / Wolanskyj-Spinner, Alexandra P / Go, Ronald S

    European journal of haematology

    2024  

    Language English
    Publishing date 2024-04-15
    Publishing country England
    Document type Letter
    ZDB-ID 392482-8
    ISSN 1600-0609 ; 0902-4441
    ISSN (online) 1600-0609
    ISSN 0902-4441
    DOI 10.1111/ejh.14212
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 323: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Ixazomib: a novel drug for multiple myeloma.

    Zanwar, Saurabh / Abeykoon, Jithma Prasad / Kapoor, Prashant

    Expert review of hematology

    2018  Volume 11, Issue 10, Page(s) 761–771

    Abstract: Introduction: Proteasome inhibitors (PIs) have been an integral part of treatment for multiple myeloma (MM) over the past decade. Many newer PIs are being evaluated in pre-clinical and clinical setting, with an aim to improve the safety, efficacy and ... ...

    Abstract Introduction: Proteasome inhibitors (PIs) have been an integral part of treatment for multiple myeloma (MM) over the past decade. Many newer PIs are being evaluated in pre-clinical and clinical setting, with an aim to improve the safety, efficacy and resistance profile of this class of drugs. Ixazomib is the first oral PI with a robust efficacy and favorable safety profile in MM. Areas covered: This review provides an overview of the (i) pharmacology and dosing of ixazomib, (ii) the efficacy and safety data from clinical studies, (iii) highlight the various novel combinations that have been reported, and (iv) give an overview of the ongoing studies with ixazomib. The review aims to provide a broad overview of the drug and compare and contrast it with the currently available alternatives. Expert commentary: The oral formulation of ixazomib makes it unique in the sense that it is an integral part of the only currently approved oral triplet for relapsed/refractory MM that incorporates both a PI and an immunomodulatory agent. The clinical efficacy, ease of administration, tolerability and synergy with other drug classes make ixazomib a valuable arsenal in the increasingly widening therapeutic armamentarium against MM.
    MeSH term(s) Administration, Oral ; Animals ; Boron Compounds/adverse effects ; Boron Compounds/therapeutic use ; Clinical Trials as Topic ; Glycine/adverse effects ; Glycine/analogs & derivatives ; Glycine/therapeutic use ; Humans ; Multiple Myeloma/drug therapy ; Protease Inhibitors/adverse effects ; Protease Inhibitors/therapeutic use
    Chemical Substances Boron Compounds ; Protease Inhibitors ; ixazomib (71050168A2) ; Glycine (TE7660XO1C)
    Language English
    Publishing date 2018-08-31
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2516804-6
    ISSN 1747-4094 ; 1747-4086
    ISSN (online) 1747-4094
    ISSN 1747-4086
    DOI 10.1080/17474086.2018.1518129
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6943: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: The Effect of Implementing Gene Expression Classifier on Outcomes of Thyroid Nodules with Indeterminate Cytology.

    Abeykoon, Jithma Prasad / Mueller, Luke / Dong, Frank / Chintakuntlawar, Ashish V / Paludo, Jonas / Mortada, Rami

    Hormones & cancer

    2016  Volume 7, Issue 4, Page(s) 272–278

    Abstract: Thyroid nodules are classified into six cytological categories under the Bethesda classification system. Two of these categories, atypical of undetermined significance (AUS) and suspicious for a follicular neoplasm (SFN), are further labeled as " ... ...

    Abstract Thyroid nodules are classified into six cytological categories under the Bethesda classification system. Two of these categories, atypical of undetermined significance (AUS) and suspicious for a follicular neoplasm (SFN), are further labeled as "indeterminate" diagnosis. Starting in June, 2012, Kansas University-Wichita Endocrine clinic implemented Afirma® Gene Expression Classifier (AGEC) to evaluate the need for surgical resection of thyroid nodules in patients with an indeterminate diagnosis. Electronic medical records of patients who underwent thyroid nodule fine-needle aspiration from 2004-2014 were reviewed. The aim of this study was to find whether implementing AGEC was associated with decreased surgical recommendation rate, decreased cost, and increased incidence of thyroid malignancy diagnosed by surgery in patients with indeterminate diagnosis. A total of 299 consecutive patients' charts were screened. Sixty-one (20 %) patients had an indeterminate diagnosis. Out of these, 27 (44 %) patients underwent evaluation before and 34 (56 %) patients underwent evaluation after AGEC implementation, respectively. Surgical recommendation for patients with indeterminate finding decreased from 81.5 to 50 % (p = 0.01) after AGEC implementation. Surgical pathology was read as malignant in 20 and 85.7 % (p < 0.01) of patients before and after AGEC implementation, respectively. Primary cost-benefit estimate showed implementing AGEC has saved $1048/patient in medical evaluation and initial management of patients with indeterminate diagnosis. AGEC implementation has decreased the number of surgical recommendations, has lowered financial burden, and has increased incidence of thyroid malignancy diagnosed by surgical pathology in patients with indeterminate diagnosis of thyroid nodules.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biopsy, Fine-Needle ; Cost-Benefit Analysis ; Female ; Gene Expression Profiling/methods ; Gene Expression Regulation, Neoplastic ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Thyroid Neoplasms/classification ; Thyroid Neoplasms/pathology ; Thyroidectomy ; Young Adult
    Language English
    Publishing date 2016-04-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2543318-0
    ISSN 1868-8500 ; 1868-8500
    ISSN (online) 1868-8500
    ISSN 1868-8500
    DOI 10.1007/s12672-016-0263-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Report of consensus panel 1 from the 11

    Buske, Christian / Castillo, Jorge J / Abeykoon, Jithma Prasad / Advani, Ranjana / Arulogun, Suzanne O / Branagan, Andrew R / Cao, Xinxin / D'Sa, Shirley / Hou, Jian / Kapoor, Prashant / Kastritis, Efstathios / Kersten, Marie J / LeBlond, Veronique / Leiba, Merav / Matous, Jeffrey V / Paludo, Jonas / Qiu, Lugui / Tam, Constantine S / Tedeschi, Alessandra /
    Thomas, Sheeba K / Tohidi-Esfahani, Ibrahim / Varettoni, Marzia / Vos, Josephine M / Garcia-Sanz, Ramon / San-Miguel, Jesus / Dimopoulos, Meletios A / Treon, Steven P / Trotman, Judith

    Seminars in hematology

    2023  Volume 60, Issue 2, Page(s) 73–79

    Abstract: Consensus Panel 1 (CP1) of the ... ...

    Abstract Consensus Panel 1 (CP1) of the 11
    MeSH term(s) Humans ; Rituximab/therapeutic use ; Waldenstrom Macroglobulinemia/drug therapy ; Waldenstrom Macroglobulinemia/genetics ; Waldenstrom Macroglobulinemia/diagnosis ; Immunoglobulin Light-chain Amyloidosis ; Consensus ; Prospective Studies ; Bendamustine Hydrochloride/therapeutic use
    Chemical Substances Rituximab (4F4X42SYQ6) ; Bendamustine Hydrochloride (981Y8SX18M)
    Language English
    Publishing date 2023-03-29
    Publishing country United States
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 206923-4
    ISSN 1532-8686 ; 0037-1963
    ISSN (online) 1532-8686
    ISSN 0037-1963
    DOI 10.1053/j.seminhematol.2023.03.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 328: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top